Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as
monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2
Diabetes for 52 weeks administration.